hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-04. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
A yeast is any species of fungus that grows primarily in a unicellular form and reproduces via budding or fission. Yeasts are eukaryotic microorganisms that originated hundreds of millions of years ago, with at least 1,500 species currently recognized. They constitute about 1% of all described fungal species. Some yeast species have the ability to develop multicellular characteristics by forming strings of connected budding cells known as pseudohyphae or false hyphae or in some cases true hyphae, or quickly evolve into a multicellular cluster with specialised cell organelle functions. Yeast sizes vary greatly, depending on species and environment, typically measuring 3–4 μm in diameter, although some yeasts can grow to 40 μm in size. Most yeasts reproduce asexually by mitosis, and many do so by the asymmetric division process known as budding. With their single-celled growth habit, yeasts can be contrasted with molds, which grow hyphae. Fungal species that can take both forms (depending on temperature or other conditions) are called dimorphic fungi. The yeast species Saccharomyces cerevisiae converts carbohydrates to carbon dioxide and alcohols through the process of fermentation. The products of this reaction have been used in baking and the production of alcoholic beverages for thousands of years. S. cerevisiae is also an important model organism in modern cell biology research, and is one of the most thoroughly studied eukaryotic microorganisms.
Early devices typically delivered low amounts of nicotine than that of traditional cigarettes, but newer devices containing a high amount of nicotine in the liquid may deliver nicotine at amounts similar to that of traditional cigarettes. Similar to traditional cigarettes, e-cigarettes rapidly delivers nicotine to the brain. The peak concentration of nicotine delivered by e-cigarettes is comparable to that of traditional cigarettes. E-cigarettes take longer to reach peak concentration than with traditional cigarettes, but they provide nicotine to the blood quicker than nicotine inhalers. The yield of nicotine users obtain is similar to that of nicotine inhalers. Newer e-cigarette models deliver nicotine to the blood quicker than with older devices. E-cigarettes with more powerful batteries can delivery a higher level of nicotine in the e-cigarette vapor. Some research indicates that experienced e-cigarette users can obtain nicotine levels similar to that of smoking. Some vapers can obtain nicotine levels comparable to smoking, and this ability generally improves with experience. E‐cigarettes users still may be able to obtain similar blood nicotine levels compared with traditional cigarettes, particularly with experienced smokers, but it takes more time to obtain such levels.
=== 2023–present === NPS was reconstituted on 6 August 2023 after Aleksić left the People's Party. Alongside Aleksić, members of the National Assembly Slavica Radovanović, Borislav Novaković, and Đorđe Stanković, and councillors in the City Assembly of Belgrade joined the party. Aleksić announced that the party would begin collecting signatures to again become a registered political party. On 25 August, Aleksić announced that they collected over 10,000 signatures. The party was subsequently registered in October 2023. NPS became part of the Serbia Against Violence coalition in October 2023, a coalition of political parties organising the 2023 protests.
Polarimeters are used in the sugar industry for determining quality of both juice from sugar cane and the refined sucrose. Often, the sugar refineries use a modified polarimeter with a flow cell (and used in conjunction with a refractometer) called a saccharimeter. These instruments use the International Sugar Scale, as defined by the International Commission for Uniform Methods of Sugar Analysis (ICUMSA).
Sources: en.wikipedia.org
== History == The first modern report of sickle cell disease may have been in 1846, where the autopsy of an executed runaway slave was discussed; the key finding was the absence of the spleen. Reportedly, African slaves in the United States exhibited resistance to malaria, but were prone to leg ulcers. The abnormal characteristics of the red blood cells, which later lent their name to the condition, were first described by Ernest E. Irons (1877–1959), intern to Chicago cardiologist and professor of medicine James B. Herrick (1861–1954), in 1910. Irons saw "peculiar elongated and sickle-shaped" cells in the blood of a man named Walter Clement Noel, a 20-year-old first-year dental student from Grenada. Noel had been admitted to the Chicago Presbyterian Hospital in December 1904 with anaemia. Noel was readmitted several times over the next three years for "muscular rheumatism" and "bilious attacks" but completed his studies and returned to the capital of Grenada (St. George's) to practice dentistry. He died of pneumonia in 1916 and is buried in the Catholic cemetery at Sauteurs in the north of Grenada. Shortly after the report by Herrick, another case appeared in the Virginia Medical Semi-Monthly with the same title, "Peculiar Elongated and Sickle-Shaped Red Blood Corpuscles in a Case of Severe Anemia." This article is based on a patient admitted to the University of Virginia Hospital on 15 November 1910. In the later description by Verne Mason in 1922, the name "sickle cell anemia" is first used.
While the 2015 DGA report does advise for a reduced level of consumption of red and processed meats, the 2015–2020 DGA key recommendations recommend that a variety of protein foods be consumed, including both vegetarian and non-vegetarian sources of protein.
Free Fluid Mechanics books Annual Review of Fluid Mechanics. Archived 2009-01-19 at the Wayback Machine. CFDWiki – the Computational Fluid Dynamics reference wiki. Educational Particle Image Velocimetry Archived 2017-08-03 at the Wayback Machine – resources and demonstrations
Sources: en.wikipedia.org
== Trivia == Guests on the album include 2006 UK DMC Champion: DJ Muzzel, legendary Jazz trumpeter Jay Phelps, composer/cellist Nicholas Singer, amongst others. Directors for the album's videos include Ebba Erikzon, Mina Song, Everton Sebben, and Mark Maclaine.
The e-cigarette vapor levels for nickel, chromium, lead, manganese surpassed occupational or environmental standards for at least 50% of the samples. The same study found 10% of the e-liquids tested contained arsenic and the amounts remained about the same as the e-cigarette vapor. The average amounts of exposure to cadmium from 1,200 e-cigarette puffs were found to be 2.6 times lower than the chronic Permissible Daily Exposure from inhalation medications, outlined by the US Pharmacopeia. One sample tested resulted in daily exposure 10% greater than chronic PDE from inhalation medications, while in four samples the amounts were comparable to outdoor air levels. Cadmium and lead have been found in the e-cigarette vapor at 2–3 times greater levels than with a nicotine inhaler. A 2015 study stated the amount of copper have been found to be six times greater than with cigarette smoke. A 2013 study stated the levels of nickel have been found to be 100 times higher than cigarette smoke. A 2014 study stated the levels of silver have been found to be at a greater amount than with cigarette smoke. Increased amounts of copper and zinc in vapor generated by some e-cigarettes may be the result of corrosion on the brass electrical connector as indicated in particulates of copper and zinc in e-liquid. In addition, a tin solder joint may be subjected to corrosion, which may result in increased amounts of tin in some e-liquids. Generally low levels of contaminates may include metals from the heating coils, solders, and wick.
Huangjiu (lit. "yellow liquor") is not distilled and is a strong rice wine (10–15% ABV). Popular brands include Shaoxing Lao Jiu, Shaoxing Hua Diao, and Te Jia Fan. While fermented grain beverages have been brewed in China for over 9,000 years, it has been long overshadowed by stronger alcohol like Baijiu and Huangjiu. In China, plum wine made from the plum blossom is called méijiǔ (梅酒).
=== Impact of Nazism === Fritz Strassmann had come to the KWIC to study under Hahn to improve his employment prospects. After the Nazi Party (NSDAP) came to power in Germany in 1933, Strassmann declined a lucrative offer of employment because it required political training and Nazi Party membership. Later, rather than become a member of a Nazi-controlled organisation, Strassmann resigned from the Society of German Chemists when it became part of the Nazi German Labour Front. As a result, he could neither work in the chemical industry nor receive his habilitation, the prerequisite for an academic position. Meitner persuaded Hahn to hire Strassmann as an assistant. Soon he would be credited as a third collaborator on the papers they produced, and would sometimes even be listed first.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.